Visium Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Visium Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-534,791	Closed	-$33.9M	–	462
2016 Q1	$33.9M	Sell	534,791 -95,143	-15%	-$6.23M	0.58%	35
2015 Q4	$70.7M	Sell	629,934 -1,119	-0.2%	-$112K	1.06%	12
2015 Q3	$60.8M	Sell	631,053 -37,185	-6%	-$4.26M	0.83%	21
2015 Q2	$68.4M	Sell	668,238 -69,258	-9%	-$5.38M	0.97%	13
2015 Q1	$45.8M	Sell	737,496 -25,906	-3%	-$1.44M	0.68%	18
2014 Q4	$33.5M	Buy	763,402 +186,867	+32%	+$8.56M	0.47%	35
2014 Q3	$32.6M	Buy	576,535 +106,121	+23%	+$5.34M	0.48%	34
2014 Q2	$21.1M	Buy	470,414 +15,305	+3%	+$630K	0.33%	51
2014 Q1	$22.3M	Buy	+455,109	New	+$23.4M	0.36%	58

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Visium Asset Management's RARE Position: Q2 2016 in Review

Visium Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2016, closing a stake of 534,791 shares — an estimated $33.9M sold.

Visium Asset Management first reported a position in RARE in Q1 2014 and held it in 9 quarters. The position peaked at $70.7M in Q4 2015. 162 funds tracked by Wall St. Rank hold RARE as of Q2 2016.

Visium Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 534,791 Ultragenyx Pharmaceutical shares in Q2 2016, an estimated $33.9M.
Visium Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 9 quarters.
Visium Asset Management's Ultragenyx Pharmaceutical position peaked at $70.7M in Q4 2015.
162 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.